Pharmaceutical

A2 Biotherapeutics raises $80m to advance CAR-T therapies for solid tumours

A2 Biotherapeutics has secured $80m in funding to advance its pipeline of CAR-T cell therapies for solid tumour cancers.

Jan 12, 2025 - 06:00
A2 Biotherapeutics raises $80m to advance CAR-T therapies for solid tumours
A2 Biotherapeutics has secured $80m in funding to advance its pipeline of CAR-T cell therapies for solid tumour cancers.
Read the original article

Tags:

Previous Article

Climb Bio enters licensing deal with Mabworks for CLYM116 development

Next Article

Light Horse emerges with $62m and Novartis partnership worth up to $1bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Regenerative medicine: new focus on VEGF target?

Regenerative medicine: new focus on VEGF target?

Mar 27, 2023

Opinion: Exceptions to abortion restrictions often fail people like Kate Cox whose babies are sure to die

Opinion: Exceptions to abortion restrictions often fail...

Dec 13, 2023

STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote

STAT+: Pharmalittle: Biden pharma patent proposal spurs...

Dec 9, 2023